IGF-1 LR3 (Long R3 Insulin-like Growth Factor 1) is a synthetic analog of human IGF-1
Testosterone Replacement Therapy (TRT)
MOTS-c is not FDA-approved for any human use as of June 2026
Research indicates that many addictive substances acutely increase dopamine signaling, although addiction also involves broader neurochemical, stress, learning, genetic, and environmental mechanisms
Its an essential nutrient that the body needs but cannot produce on its own, so it must be obtained through diet or supplements
However, compared to their effects on CAD and stroke, there is relatively limited data regarding the impact of GLP-1RAs on PAD outcomes